CareDx applauds HHS Report on Cost Savings of Lifetime Immunosuppressive Drug Coverage for Transplant Patients
May 14 2019 - 8:33AM
CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics
company focused on the discovery, development, and
commercialization of clinically differentiated, high-value
diagnostic solutions for transplant patients, applauds the
Department of Health and Human Services for releasing a report
highlighting the cost savings of lifetime immunosuppressive drug
coverage for transplant patients.
CareDx is dedicated to improving the long-term health outcomes
of transplant recipients. A critical part of protecting a donated
kidney is appropriate dosage of immunosuppressant drugs for the
life of the recipient, treatment financially out of reach for many
individuals without insurance coverage. For this reason, CareDx has
been urging Congress to pass legislation to extend Medicare
coverage of immunosuppressive medication for kidney transplant
recipients beyond the current three-year cap. CareDx is sponsoring
the Honor the Gift campaign, a national patient-centered campaign
promoted by a coalition of kidney and transplant organizations to
advocate for the bill in Congress.
“The analysis is potentially game changing for the prospects of
the bill’s passage. The cost associated with this change has
thwarted its passage in the past. Assuming the Congressional Budget
Office can agree with ASPE’s analytical assumptions, a cost-saving
bill could easily be included in legislative packages moving
forward,” said Peter Maag, CEO of CareDx. “We urge Congress to
capitalize on this analysis by quickly introducing and passing the
necessary legislation. The gift of a donated kidney should be
protected at all costs, but when the right treatment also saves
money, there is a moral obligation to do the right thing. Ensuring
transplant patients have access to these life-saving medications
will help protect patients, honor the gift of their donors, and
will save the taxpayers money.”
Learn more about CareDx’s work to extend Medicare coverage of
immunosuppressive medications for kidney transplant recipients
at HonorTheGift.org.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular
diagnostics company focused on the discovery, development and
commercialization of clinically differentiated, high-value
diagnostic solutions for transplant recipients. CareDx offers
products along the pre- and post-transplant testing continuum, and
is the leading provider of genomics-based information for
transplant patients.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements,
including statements regarding the Company’s participation in the
Honor the Gift campaign. These forward-looking statements are based
upon information that is currently available to CareDx and its
current expectations, speak only as of the date hereof, and are
subject to numerous risks and uncertainties, including general
economic and market factors, among others discussed in CareDx’s
filings with the SEC, including the Annual Report on Form 10-K for
the fiscal year ended December 31, 2018 filed by CareDx with the
SEC on March 6, 2019 and the periodic reports that CareDx has
subsequently filed with the SEC. Any of these may cause CareDx’s
actual results, performance or achievements to differ materially
and adversely from those anticipated or implied by CareDx’s
forward-looking statements. CareDx expressly disclaims any
obligation, except as required by law, or undertaking to update or
revise any such forward-looking statements.
CONTACTS:
CareDx, Inc.Sasha KingChief Commercial
Officer415-287-2393sking@caredx.com
Investor RelationsDavid ClairIntegrated Corporate Relations,
Inc.646-277-1266david.clair@icrinc.com
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Apr 2023 to Apr 2024